Eli Lilly (LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on ...

Omvoh® is now indicated for both major forms of Inflammatory Bowel Disease (IBD) – ulcerative colitis (UC) and Crohn’s ...

今日，礼来宣布，美国FDA已经批准Omvoh（mirikizumab）用于治疗成人中度至重度活动性克罗恩病（CD）。 这是继Omvoh于2023年10月首次获得FDA批准后的第二 ...

--Eli Lilly and Company announced today that the U.S. Food and Drug Administration has approved Omvoh™ infusion/ injection, the first and only interleukin-23p19 antagonist for the treatment of ...

Lilly has also submitted marketing applications for Omvoh in Crohn's disease around the globe, including in the European Union and Japan. Additional global regulatory submissions are planned.

Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug ...

Lilly has also submitted Omvoh in the U.S. for approval to treat adults with moderately to severely active Crohn's disease, with a decision expected in the first half of 2025.

Lilly's first approved treatment for a type of inflammatory bowel disease INDIANAPOLIS, Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug ...

Eli Lilly won Food and Drug Administration approval to sell its Omvoh medicine for adults with Crohn’s disease, adding to the potential market for a drug first approved in 2023.